What is the clinical evidence from this study?

Study design: Cohort. Population: Type 2 diabetes (n=42101). Intervention: Fenofibrate vs. Statins. Primary outcome: Incident sight-threatening diabetic retinopathy (STDR) (aHR 0.87, 95% CI 0.82-0.93).

What does this research mean for the field?

Fenofibrate use reduces the risk of sight-threatening diabetic retinopathy in individuals with type 2 diabetes compared to statin therapy in real-world clinical practice. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess real-world comparative effectiveness of fenofibrate versus statins on the incidence of sight-threatening diabetic retinopathy in adults with type 2 diabetes.

September 8, 2026The Journal of Clinical Endocrinology & MetabolismOpen Access

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence

View Full Paper

Ask AI

Bookmark

Key result

Fenofibrate linked to ~13% lower risk of sight-threatening diabetic retinopathy vs. statins.

aHR 0.87
95% CI 0.82-0.93
n=42,101

Why the study?

Does fenofibrate reduce the risk of incident sight-threatening diabetic retinopathy in adults with type 2 diabetes compared to statins?

Population

Adults (≥18 years) with type 2 diabetes (T2D), n=42,101

Comparison

Fenofibrate vs Statins

Design

Cohort

Follow-up

up to 12 years

Authors

LTLuyuan TanSun Yat-sen University JCJennifer CooperNorthwestern University KGKrishna GokhaleBirmingham City University

Discussion

Member takes

Implication

In a real-world setting, fenofibrate use is associated with a significantly reduced risk of sight-threatening diabetic retinopathy in patients with type 2 diabetes compared to statin use.

Key Points

To assess real-world comparative effectiveness of fenofibrate versus statins on the incidence of sight-threatening diabetic retinopathy in adults with type 2 diabetes.
Propensity score-matched, prevalent new-user comparative effectiveness trial emulation study using UK Clinical Practice Research Datalink primary care records from 1 January 2000 to 30 June 2022.
Included 16,337 fenofibrate new users matched with 25,764 statin users aged ≥18 years with type 2 diabetes, followed for up to 12 years.
Estimated crude and adjusted hazard ratios (aHR) for incident sight-threatening diabetic retinopathy using competing risk Cox proportional hazard regression models in intention-to-treat (ITT) and per-protocol (PP) analyses.
Fenofibrate use significantly lowered the risk of developing sight-threatening diabetic retinopathy compared to statin use (aHR: ITT 0.87, 95% CI 0.82–0.93; PP 0.80, 95% CI 0.74–0.87).
Risk reductions remained consistent across sensitivity analyses and subgroups defined by age, sex, and baseline lipid levels, though protective effects were not observed in South Asian participants.

Study Design

Type

Cohort (n=42,101)

Multicenter

Yes

Structured PICO

Does fenofibrate reduce the risk of incident sight-threatening diabetic retinopathy in adults with type 2 diabetes compared to statins?

Population

42,101 adults with type 2 diabetes receiving either fenofibrate or statins, followed for up to 12 years.

Exposure

Fenofibrate

Comparator

Statins

Outcome

Incident sight-threatening diabetic retinopathy (STDR)hard clinical

Main Result

Hazard Ratio: 0.87 (95% CI 0.82–0.93)

In a real-world setting, fenofibrate use is associated with a significantly reduced risk of sight-threatening diabetic retinopathy in patients with type 2 diabetes compared to statin use.

Cite This Study

Tan et al. (2026) conducted a cohort in Type 2 diabetes (n=42,101). Fenofibrate vs. Statins was evaluated on Incident sight-threatening diabetic retinopathy (STDR) (aHR 0.87, 95% CI 0.82-0.93). Fenofibrate use was associated with a reduced risk of incident sight-threatening diabetic retinopathy compared with statins in adults with type 2 diabetes (aHR 0.87; 95% CI 0.82-0.93).

synapsesocial.com/papers/6a9fd81458e84d0ff5b473fa https://doi.org/10.1210/clinem/dgag367

View Full Paper

Ask AI

Bookmark

Implication

In a real-world setting, fenofibrate use is associated with a significantly reduced risk of sight-threatening diabetic retinopathy in patients with type 2 diabetes compared to statin use.

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Associations between fenofibrate use and sight-threatening diabetic retinopathy in type 2 diabetes: UK real-world evidence

Discussion

Member takes

Implication

Key Points

Study Design

Structured PICO

Main Result

Cite This Study

Also Consider

Also Consider